Möchten Sie immer auf dem neuesten Stand bleiben?

Longeveron Chief Science Officer and Chief Medical Officer selected as speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum (Dec 8-10).

Longeveron granted Canadian patent for method of using stem cells to treat patients with aging-related frailty and also for the treatment of NIDCM.

Circle CVI highlights innovations to boost efficiency, accuracy, and practice growth in cardiac imaging. Join them at RSNA to see the latest advancements.

 November 17, 2025Innovation uses AI to track and visualize tiny repair devices* through the beating heart, helping clinicians navigate in 3D with enhanced clarity and confidence**Amsterdam, the...

NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- A tailored approach of vitamin D3 supplementation in patients who have suffered a heart attack significantly reduces their risk of a second heart...

London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, today presented long-term...

LithiX™ HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques MY-IVL study enrolled 102 real...

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations...

Circle CVI has received FDA 510(k) clearance for cvi42 | Plaque, its AI-enabled coronary plaque analysis solution.

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant...